Helen Louise Collins sold $1.2M of Enliven Therapeutics (ELVN)

Executed Feb 17, disclosed Feb 19, 2 days later.

Value, as filed

$1.2M

45,000 sh × $26.17

Executed

Feb 17

the trade date, as filed

Disclosed

Feb 19

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Helen Louise Collins CHIEF MEDICAL OFFICER profile →

Helen Louise Collins (CHIEF MEDICAL OFFICER) filed 10 Form 4 reports in the trailing twelve months (0 purchases, 10 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $1.4M of ELVN (40,000 sh × $35.10, as filed), executed Mar 25.

The name

ELVN

Enliven Therapeutics, Inc. ELVN · Healthcare · 61 filings in 24 months ticker →

Healthcare · Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibito…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Helen Louise Collins in ELVN

ELVNSALE Enliven Therapeutics, Inc. $146K
2,916 sh × $50.03
Exec Sep 17
Filed Sep 21 · 5:22 PM ET ELVNSALE Enliven Therapeutics, Inc. $228K
3,900 sh × $58.37
Exec Aug 17
Filed Aug 19 · 4:16 PM ET ELVNSALE Enliven Therapeutics, Inc. $225K
4,247 sh across 2 lots
Exec Jul 17
Filed Jul 21 · 5:23 PM ET ELVNSALE Enliven Therapeutics, Inc. $114K
2,599 sh × $43.87
Exec Jun 17
Filed Jun 22 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $137K
3,475 sh × $39.53
Exec May 18
Filed May 20 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $232K
4,860 sh across 2 lots
Exec Apr 17
Filed Apr 21 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $1.4M
40,000 sh × $35.10
Exec Mar 25
Filed Mar 27 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $139K
5,000 sh × $27.76
Exec Mar 17
Filed Mar 19 · 5:30 PM ET